Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease.
The Phase IIa COURSE trial was a.
AstraZeneca presents its latest research on major respiratory and immune diseases at ATS 2024.AstraZeneca will present new clinical and real-world data on its respiratory inhalation, biologics and.